Literature DB >> 10821883

Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34).

T Hirano1, D B Burr, R L Cain, J M Hock.   

Abstract

The purpose of this study was to determine if the increased cortical bone porosity induced by intermittently administered parathyroid hormone (PTH) reduces bone strength significantly. Mature ovary-intact New Zealand white rabbits were treated with once daily injections of vehicle, or PTH(1-34), LY333334, at 10 or 40 microg/kg/day for 140 days. Geometry of the femoral midshaft was measured to evaluate changes in the cross-sectional moment of inertia (CSMI). Cortical porosity was measured in the midshaft of the tibia by dividing cortical area into three zones based on equal divisions of cortical diameter: near endocortical (Zone I), near intermediate (Zone II), and near periosteal (Zone III) regions. Total cortical porosity significantly increased after PTH treatment from 1.4% in the controls to 6.3% in the higher dose group, but the location of the new porosities was not randomly distributed. In the controls, porosity of Zones I and II (both 1.7%) was almost twice as much as that of Zone III (0.9%). In the lower dose group, cortical porosity of Zone I (5.5%) and II (1.8%) was greater than in Zone III (0.9%), but these differences were not statistically significant. In the higher dose group, cortical porosity of Zone I (11.5%) and II (6. 1%) significantly increased compared with Zone III (1.4%) (P < 0. 0005). Histomorphometric measurements showed that bone formation rate on both periosteal and endocortical surfaces increased, resulting in increased bone area and cortical area in the higher dose group. A model was developed to evaluate the effect of the changes in geometry and porosity on CSMI in the different zones. This simulation model indicated that CSMI in the higher dose group was significantly greater than in the other two groups, despite the increased porosity. We speculate the reason to be that porosity increased near the endocortical surface, where its mechanical effect is small. This increase was more than offset by apposition of new bone on the periosteal surface. These data suggest that (1) PTH increases cortical porosity in a dose-dependent manner, primarily near endocortical surfaces; (2) because of this nonhomogeneous distribution, the mechanical effect of increased porosity is small; (3) the increased cortical porosity associated with PTH treatment is more than offset by periosteal apposition of new bone, causing an overall increase in the bending rigidity of cortical bone; and (4) these changes cannot be accurately evaluated using noninvasive methods of bone densitometry, which cannot account for the location of bone gain and bone loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821883     DOI: 10.1007/s002230010091

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  15 in total

1.  A case of primary hyperparathyroidism with marked changes in bone mineral density and geometry after parathyroidectomy.

Authors:  Hiroshi Kaji; Mei-Fway Iu; Junko Naito; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Experimental perspective on fallback foods and dietary adaptations in early hominins.

Authors:  Jeremiah E Scott; Kevin R McAbee; Meghan M Eastman; Matthew J Ravosa
Journal:  Biol Lett       Date:  2014-01-08       Impact factor: 3.703

3.  beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice.

Authors:  Mary L Bouxsein; Dominique D Pierroz; Vaida Glatt; Deborah S Goddard; Fanny Cavat; Renée Rizzoli; Serge L Ferrari
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

Review 4.  Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size.

Authors:  David B Burr
Journal:  Curr Osteoporos Rep       Date:  2005-03       Impact factor: 5.096

5.  Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration.

Authors:  Mami Ogita; Marie Therese Rached; Elzbieta Dworakowski; John P Bilezikian; Stavroula Kousteni
Journal:  Endocrinology       Date:  2008-07-10       Impact factor: 4.736

6.  Effect of intermittent treatment with human Parathyroid Hormone 1-34 in SAMP6 senescence-accelerated mice.

Authors:  Y Washimi; H Chen; A Ito; R Takao; T Uzawa; Y Yamamoto; H Yamada; S Shoumura
Journal:  J Endocrinol Invest       Date:  2009-11-12       Impact factor: 4.256

7.  Cortical bone vessel identification and quantification on contrast-enhanced MR images.

Authors:  Po-Hung Wu; Matthew Gibbons; Sarah C Foreman; Julio Carballido-Gamio; Misung Han; Roland Krug; Jing Liu; Thomas M Link; Galateia J Kazakia
Journal:  Quant Imaging Med Surg       Date:  2019-06

8.  Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling.

Authors:  Marcus Watkins; Susan K Grimston; Jin Yi Norris; Bertrand Guillotin; Angela Shaw; Elia Beniash; Roberto Civitelli
Journal:  Mol Biol Cell       Date:  2011-02-23       Impact factor: 4.138

9.  PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.

Authors:  Yumie Rhee; Matthew R Allen; Keith Condon; Virginia Lezcano; Ana C Ronda; Carlo Galli; Naomi Olivos; Giovanni Passeri; Charles A O'Brien; Nicoletta Bivi; Lilian I Plotkin; Teresita Bellido
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

10.  Chewed out: an experimental link between food material properties and repetitive loading of the masticatory apparatus in mammals.

Authors:  Matthew J Ravosa; Jeremiah E Scott; Kevin R McAbee; Anna J Veit; Annika L Fling
Journal:  PeerJ       Date:  2015-11-03       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.